Weider marketing plans
This article was originally published in The Tan Sheet
October print ads will support launch of Schiff Prostate Health, relaunch of Breast Health, supplement firm says Sept. 26 in announcing fiscal first quarter financial results. Hitting shelves by early December, Prostate Health contains lycopene, saw palmetto, calcium d-glucarate, while Breast Health features calcium d-glucarate, soy isoflavones, antioxidants. One-month supply of each will retail for $15, firm says. Weider plans to "significantly ramp up" marketing spending for Schiff line in mid-Q2. Net sales for division were up 1.5% to $41.2 mil. due to greater sales incentives, promotions, firm notes. Move Free line sales decreased 4.6% to $18.7 mil. due to private label competition. Move Free Triple Strength, which offers same amount of glucosamine/chondroitin in two tablets rather than three, debuted in late summer and is expanding distribution, Weider notes...
You may also be interested in...
Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics.
The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.
Limiting interactions to two-dimensional settings will hinder collaboration, innovation and the mentoring of younger employees, Merck & Co. CEO Kenneth Frazier says. Frazier, who will retire in June, is looking forward to returning to public service but says "politics with a capital P is not my thing."